Initial Prostate Specific Antigen 1.5 ng/ml or Greater in Men 50 Years Old or Younger Predicts Higher Prostate Cancer Risk

被引:18
|
作者
Tang, Ping
Sun, Leon
Uhlman, Matthew A.
Robertson, Cary N.
Polascik, Thomas J.
Albala, David M.
Donatucci, Craig F.
Moul, Judd W.
机构
[1] Duke Univ, Med Ctr, Div Urol, Dept Surg, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Duke Prostate Ctr, Durham, NC 27710 USA
来源
JOURNAL OF UROLOGY | 2010年 / 183卷 / 03期
关键词
prostate; prostatic neoplasms; prostate-specific antigen; mass screening; continental population groups; AMERICANS; MORTALITY; COHORT; TRIAL; WHITE; LESS;
D O I
10.1016/j.juro.2009.11.021
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Studies show that initial prostate specific antigen higher than the median in young men predicts a subsequent higher risk of prostate cancer. To our knowledge this relationship has not been studied in patients stratified by race. Materials and Methods: A cohort of 3,530 black and 6,118 white men 50 years or younger with prostate specific antigen 4 ng/ml or less at the first prostate specific antigen screening was retrieved from the prostate center database at our institution. Patients were divided into groups based on initial prostate specific antigen 0.1 to 0.6, 0.7 to 1.4, 1.5 to 2.4 and 2.5 to 4.0 ng/ml. Univariate and age adjusted multivariate logistic regression was done to estimate the cancer RR in these prostate specific antigen groups. We calculated the prostate cancer rate at subsequent followups. Results: Median prostate specific antigen in black and white men was 0.7 ng/ml at age 50 years or less. The prostate cancer rate was not significantly different in the groups with prostate specific antigen less than 0.6 and 0.7 to 1.4 ng/ml in black or white men. Black and white men with initial prostate specific antigen in the 1.5 to 2.4 ng/ml range had a 9.3 and 6.7-fold increase in the age adjusted prostate cancer RR, respectively. At up to 9 years of followup initial prostate specific antigen 1.5 ng/ml or greater was associated with gradually increased detection at follow-up in black and white men. Conclusions: An initial prostate specific antigen cutoff of 1.5 ng/ml may be better than median prostate specific antigen 0.7 ng/ml to determine the risk of prostate cancer in black and white men 50 years old or younger.
引用
收藏
页码:946 / 950
页数:5
相关论文
共 50 条
  • [31] Predicting Prostate Biopsy Result in Men With Prostate Specific Antigen 2.0 to 10.0 ng/ml Using an Investigational Prostate Cancer Methylation Assay
    Baden, Jonathan
    Adams, Scott
    Astacio, Tara
    Jones, Jennifer
    Markiewicz, Jadwiga
    Painter, Jennifer
    Trust, Carrie
    Wang, Yixin
    Green, George
    JOURNAL OF UROLOGY, 2011, 186 (05): : 2101 - 2106
  • [32] Usefulness of Prostate Specific Antigen Density in Prostate Cancer Detection among Men with PSA of 4-10 ng/ml
    Agbo, C. A.
    Ramyil, V. M.
    Dakum, N. K.
    Shuaibu, S., I
    Akpayak, I. C.
    Ofoha, C. G.
    Onowa, V. E.
    Nabasu, L. E.
    Galam, Z. Z.
    ANNALS OF MEDICAL AND HEALTH SCIENCES RESEARCH, 2020, 10 (05) : 1138 - 1141
  • [33] Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen
    Catalona, WJ
    Bartsch, G
    Rittenhouse, HG
    Evans, CL
    Linton, HJ
    Horninger, W
    Klocker, H
    Mikolajczyk, SD
    JOURNAL OF UROLOGY, 2004, 171 (06): : 2239 - 2244
  • [34] Clinically Significant Prostate Cancer is Rarely Missed by Ablative Procedures of the Prostate in Men with Prostate Specific Antigen Less Than 4 ng/ml
    Meeks, Joshua J.
    Maschino, Alexandra C.
    McVary, Kevin T.
    Sandhu, Jaspreet S.
    JOURNAL OF UROLOGY, 2013, 189 (01): : 111 - 115
  • [35] Transrectal Saturation Technique May Improve Cancer Detection as an Initial Prostate Biopsy Strategy in Men with Prostate-specific Antigen <10 ng/ml
    Li, Yong-Hong
    Elshafei, Ahmed
    Li, Jianbo
    Gong, Michael
    Susan, Luay
    Fareed, Khaled
    Jones, J. Stephen
    EUROPEAN UROLOGY, 2014, 65 (06) : 1178 - 1183
  • [36] Risk Profiles and Treatment Patterns Among Men Diagnosed as Having Prostate Cancer and a Prostate-Specific Antigen Level Below 4.0 ng/mL
    Shao, Yu-Hsuan
    Albertsen, Peter C.
    Roberts, Calpurnyia B.
    Lin, Yong
    Mehta, Amit R.
    Stein, Mark N.
    DiPaola, Robert S.
    Lu-Yao, Grace L.
    ARCHIVES OF INTERNAL MEDICINE, 2010, 170 (14) : 1256 - 1261
  • [37] Use of 2.6 Ng/Ml prostate specific antigen prompt for biopsy in men older than 60 years
    Nadler, RB
    Loeb, S
    Roehl, KA
    Antenor, JAV
    Eggener, S
    Catalona, WJ
    JOURNAL OF UROLOGY, 2005, 174 (06): : 2154 - 2157
  • [38] Percent Free Prostate-Specific Antigen (PSA) Is an Accurate Predictor of Prostate Cancer Risk in Men With Serum PSA 2.5 ng/mL and Lower
    Waiz, Jochen
    Haese, Alexander
    Scattoni, Vincenzo
    Steuber, Thomas
    Chun, Felix K. H.
    Briganti, Alberto
    Montorsi, Francesco
    Graefen, Markus
    Huland, Hartwig
    Karakiewicz, Pierre I.
    CANCER, 2008, 113 (10) : 2695 - 2703
  • [39] Detection of prostate cancer in men with prostate-specific antigen (PSA) levels of 2.0 to 4.0ng/ml is equivalent to that in men with 4.1 to 10.0ng/ml in a Japanese population
    Kobayashi, T
    Nishizawa, K
    Mitsumori, K
    Ogura, K
    Ide, Y
    JOURNAL OF UROLOGY, 2004, 171 (04): : 478 - 479
  • [40] Oncological and peri-surgical outcomes of radical prostatectomy for non-metastatic prostate cancer with prostate-specific antigen level of 50 ng/ml or greater
    Makino, Katsuhiro
    Nakagawa, Tohru
    Ito, Eisaku
    Kasahara, Ichiro
    Murata, Takashi
    Fujimura, Tetsuya
    Fukuhara, Hiroshi
    Homma, Yukio
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (05) : 485 - 490